| Title: |
Global estimates and determinants of antituberculosis drug pharmacokinetics in children and adolescents: a systematic review and individual patient data meta-analysis. |
| Authors: |
Gafar, F; Wasmann, RE; McIlleron, HM; Aarnoutse, RE; Schaaf, HS; Marais, BJ; Agarwal, D; Antwi, S; Bang, ND; Bekker, A; Bell, DJ; Chabala, C; Choo, L; Davies, GR; Day, JN; Dayal, R; Denti, P; Donald, PR; Engidawork, E; Garcia-Prats, AJ; Gibb, D; Graham, SM; Hesseling, AC; Heysell, SK; Idris, MI; Kabra, SK; Kinikar, A; Kumar, AKH; Kwara, A; Lodha, R; Magis-Escurra, C; Martinez, N; Mathew, BS; Mave, V; Mduma, E; Mlotha-Mitole, R; Mpagama, SG; Mukherjee, A; Nataprawira, HM; Peloquin, CA; Pouplin, T; Ramachandran, G; Ranjalkar, J; Roy, V; Ruslami, R; Shah, I; Singh, Y; Sturkenboom, MGG; Svensson, EM; Swaminathan, S; Thatte, U; Thee, S; Thomas, TA; Tikiso, T; Touw, DJ; Turkova, A; Velpandian, T; Verhagen, LM; Winckler, JL; Yang, H; Yunivita, V; Taxis, K; Stevens, J; Alffenaar, J-WC; Global Collaborative Group for Meta-Analysis of Paediatric Individual Patient Data in Pharmacokinetics of Anti-TB Drugs |
| Publisher Information: |
European Respiratory Society |
| Publication Year: |
2023 |
| Collection: |
The University of Melbourne: Digital Repository |
| Description: |
BACKGROUND: Suboptimal exposure to antituberculosis (anti-TB) drugs has been associated with unfavourable treatment outcomes. We aimed to investigate estimates and determinants of first-line anti-TB drug pharmacokinetics in children and adolescents at a global level. METHODS: We systematically searched MEDLINE, Embase and Web of Science (1990-2021) for pharmacokinetic studies of first-line anti-TB drugs in children and adolescents. Individual patient data were obtained from authors of eligible studies. Summary estimates of total/extrapolated area under the plasma concentration-time curve from 0 to 24 h post-dose (AUC0-24) and peak plasma concentration (C max) were assessed with random-effects models, normalised with current World Health Organization-recommended paediatric doses. Determinants of AUC0-24 and C max were assessed with linear mixed-effects models. RESULTS: Of 55 eligible studies, individual patient data were available for 39 (71%), including 1628 participants from 12 countries. Geometric means of steady-state AUC0-24 were summarised for isoniazid (18.7 (95% CI 15.5-22.6) h·mg·L-1), rifampicin (34.4 (95% CI 29.4-40.3) h·mg·L-1), pyrazinamide (375.0 (95% CI 339.9-413.7) h·mg·L-1) and ethambutol (8.0 (95% CI 6.4-10.0) h·mg·L-1). Our multivariate models indicated that younger age (especially |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| ISSN: |
0903-1936 |
| Relation: |
https://hdl.handle.net/11343/350456 |
| Availability: |
https://hdl.handle.net/11343/350456 |
| Rights: |
https://creativecommons.org/licenses/by-nc/4.0 ; CC BY-NC |
| Accession Number: |
edsbas.FEC1A230 |
| Database: |
BASE |